Robert Alan Figlin MD FACP (He/Him)
Genitourinary Oncology, Hematologic Oncology, Thoracic Cancer
Steven Spielberg Family Chair in Hematology-Oncology Professor, Biomedical Sciences Professor, Medicine Cedars-Sinai Medical Center Professor Emeritus, Medicine and Urology, David Geffen School of Medicine, UCLA Deputy Director, the Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center Deputy Director, Cedars-Sinai Cancer, Cedars-Sinai Health System, Los Angeles, CA
Join to view full profile
8700 Beverly Blvd.N. Tower, LL, AC1085Los Angeles, CA 90048
Phone+1 310-423-1331
Fax+1 310-248-6990
Dr. Figlin is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Robert Figlin, based in Los Angeles, CA, specializes in oncology with subspecialties in genitourinary, hematologic, and thoracic cancers. His medical training includes a hematology and medical oncology fellowship at UCLA and an internal medicine residency and chief residency at Cedars-Sinai Medical Center. Dr. Figlin has expertise in neuro-oncology, hematologic oncology, breast cancer, and renal cell carcinoma. His work has been published in journals like The Lancet Oncology, Nature Reviews Urology, and the Journal of Clinical Oncology. He has led several clinical trials focusing on advanced renal cell carcinoma and non-small cell lung cancer. He holds multiple CMS Meaningful Use Stage 1 Certifications from Epic Systems Corporation and Sunquest Information Systems.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1980 - 1982
Cedars-Sinai Medical CenterChief Residency, Internal Medicine, 1979 - 1980- Cedars-Sinai Medical CenterResidency, Internal Medicine, 1976 - 1979
MCP-Hahnemann College of MedicineClass of 1976
Certifications & Licensure
CA State Medical License 1977 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification Outgoing Public Health Reporting from EpicCare Functionality, Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- Tumoricidal efficacy of DZ-1 dye conjugated to dihydroartemisinin in patient-derived colorectal liver metastasis tumoroids.Farzaneh Vafaeinik, Badrinath Narayanasamy, Sarah Helmueller, Yi Zhang, Alexandra Gangi
Molecular Therapy. Oncology. 2026-09-17 - 1 citationsBelzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled...Robert J Motzer, Ray McDermott, Se Hoon Park, Mauricio Burotto, Roberto Iacovelli
Lancet. 2026-08-29 - Linker-dependent variations in the tumoricidal activity of DZ-1-dihydroartemisinin conjugate formats.Farzaneh Vafaeinik, Sarah Helmueller, Yi Zhang, Alexandra Gangi, Heuiran Lee
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2026-08-01
Press Mentions
Is It Time for a New Type of Cancer Physician?August 20th, 2026- 17 Books Oncologists Recommend for Summer 2026August 5th, 2026
- “Sobering” Takeaway From ASCO 2026: Concerns About Clinical Trial ParticipationJune 29th, 2026
Grant Support
- LATE Stage Lung CancerNational Cancer Institute2011
- Cancer Center Support GrantNational Cancer Institute2007–2009
- Oncology Research Career Development ProgramNational Cancer Institute2006–2007
- Phase II Trial Of Recombinant Human Granulocyte MacropNational Center For Research Resources2004
- Core--Clinical Research UnitNational Cancer Institute1994–2002
Professional Memberships
- Member
Industry Relationships
- Board of directors, 4D MedicalNext generation lung imaging company.2018 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: